HIV / AIDS in the News

Switching to Bictegravir-Lenacapavir Combination Maintains HIV Virologic Suppression in Complex Regimen Patients - Contagion Live

 

what happens if Ryan White ends for HIV AIDS - Infectious Disease Special Edition

 

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing - Business Wire

 

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen - Business Wire

 

Once‑every‑4‑months HIV regimen holds virus at bay in ViiV study - Stock Titan

 

Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1 - Yahoo Finance

 

Gilead paints clearer picture of next-gen HIV tablet's prowess with results from 2 late-stage studies - Fierce Pharma

 

Single daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens - Medical Xpress

 

New single-pill HIV therapy promises boost for long-term virus survivors - Financial Times

 

A single once-daily pill combining two antiretrovirals simplifies HIV treatment, as demonstrated by a phase 3 trial - Science Media Centre España

 

US funding freeze linked to HIV care disruptions in 32 countries, study finds - Medical Xpress

 

How can PrEP use among Black people be improved? - Advocate.com

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Two-drug HIV pill from Merck rivals standard treatment in trials - Stock Titan

 

Age, HIV, and Metabolic Syndrome Together Tied to Cognitive Impairment Risk - MedPage Today

 

Tacoma City Council approves funding for HIV, STI self-testing for LGBTQ+ youth - KOMO

 

Funding cuts are devastating Black HIV prevention work. But activists say pressure is working. - LGBTQ Nation

 

DOR/ISL Phase III data underlines trend for shift towards two-drug STRs in HIV - Clinical Trials Arena